Vivity Study in Taiwan

This study was a prospective, single arm study. The inclusion criteria for this study were the presence of cataracts in both eyes and corrected distance visual acuity (CDVA) of both eyes under 20/40, who received bilateral Vivity IOL implantation after cataract surgery, targeting emmetropia or mini-monovision of both eyes. Phacoemulsification cataract surgery was performed on all patients. The exclusion criteria were complicated cataract; corneal opacities or irregularities; severe dry eye (Schirmer's test I ≤ 5 mm); amblyopia; anisometropia; surgical complications such as posterior capsular bag rupture, vitreous loss, or IOL tilt/decentration; coexisting ocular pathologies such as glaucoma, nondilating pupil, history of intraocular surgery, refractive surgery, or retinopathy; optic nerve or macular diseases; and refusal or inability to maintain follow-up. When corneal astigmatism was more than 0.75 diopters (D), a toric IOL was implanted.

Inclusion criteria

• Patients with age-related cataract requiring surgery treatment
• Patient who received bilateral, uneventful implantation of Vivity IOLs
• Patient's IOL power is between 10-30D, and T2-T6 for toric correction
• Cataract grade 0~3 based on the Wisconsin cataract grading system

• Exclusion criteria:
• Cataract grade 4~5 based on the Wisconsin cataract grading system
• Patient's IOL power is outside of 10-30D or T2-T6 for toric correction
• Patient with the following ocular comorbidities:
• Corneal opacities or irregularities;
• Severe dry eye;
• Amblyopia;
• Glaucoma;
• Non-dilating pupil;
• History of intraocular surgery, laser therapy, or retinopathy;
• Optic nerve or macular diseases;
• Uncontrolled diabetic mellitus or systemic immune disease;
• Refusal or unable to maintain follow-up